SCHEMBL762953

SCHEMBL762953

CC(C)(C)C(=O)OCOP(=O)(OCOC(=O)C(C)(C)C)C(CCCc1cccc(Oc2ccccc2)c1)S(=O)(=O)O

nearest known ligand 0.53

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
FDFT1 P37268 14/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8824807 1.00 FDFT1 (0.53) FDFT1
SCHEMBL16366775 0.96 FDFT1 (0.48) FDFT1
SCHEMBL12873126 0.95 FDFT1 (0.48) FDFT1
SCHEMBL13552731 0.89 FDFT1 (0.49) FDFT1
SCHEMBL1097155 0.89 FDFT1 (0.48) FDFT1
SCHEMBL8897991 0.88 FDFT1 (0.50) FDFT1
SCHEMBL8897781 0.88 FDFT1 (0.50) FDFT1
SCHEMBL14106669 0.88 FDFT1 (0.48) FDFT1
SCHEMBL8897832 0.87 FDFT1 (0.49) FDFT1
SCHEMBL8898234 0.86 FDFT1 (0.53) FDFT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 512 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5470845-A Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia BRISTOL-MYERS SQUIBB COMPANY (US) 1995-11-28 US claimed
EP-0595635-A1 Alpha-phosphorous substituted sulfonate derivatives as squalene synthetase inhibitors E.R. Squibb & Sons, Inc. (US) 1994-05-04 EP claimed
EP-2582709-B1 AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES SANOFI SA (FR) 2018-01-24 EP disclosed
EP-2683698-B1 BENZYL-OXATHIAZINE DERIVATES SUBSTITUTED WITH ADAMANTANE OR NORADAMANTANE, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF SANOFI SA (FR) 2017-10-04 EP disclosed
EP-2897939-B1 BENZOIMIDAZOLE-CARBOXYLIC ACID AMIDE DERIVATIVES FOR TREATING METABOLIC OR CARDIOVASCULAR DISEASES SANOFI SA (FR) 2017-02-01 EP disclosed
EP-2203415-B1 (CYCLOPROPYL-PHENYL)-PHENYL-OXALAMIDES, METHOD FOR THEIR MANUFACTURE AND THEIR APPLICATION AS MEDICINES SANOFI SA (FR) 2016-10-26 EP disclosed
EP-2144885-B1 IMIDAZOLIDINE CARBOXAMIDE DERIVATIVES AS LIPASE AND PHOSPHOLIPASE INHIBITORS SANOFI SA (FR) 2016-06-29 EP disclosed
EP-2144891-B1 5-OXO-ISOXAZOLES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES SANOFI SA (FR) 2016-06-15 EP disclosed
EP-2847191-B1 SUBSTITUTED 6-(4-HYDROXY-PHENYL)-1H-PYRAZOLO[3,4-B]PYRIDINE DERIVATIVES AS KINASE INHIBITORS SANOFI SA (FR) 2016-06-15 EP disclosed
EP-2766349-B1 OXATHIAZINE DERIVATIVES SUBSTITUTED WITH CARBOCYCLES OR HETEROCYCLES, METHOD FOR PRODUCING SAME, DRUGS CONTAINING SAID COMPOUNDS, AND USE THEREOF SANOFI SA (FR) 2016-06-01 EP disclosed
EP-2771340-B1 6-(4-HYDROXY-PHENYL)-1H-PYRAZOLO[3,4-B]PYRIDINE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS KINASE INHIBITORS SANOFI SA (FR) 2016-04-13 EP disclosed
WO-2006099940-A1 SUBSTITUTED, BICYCLIC 8-PYRROLIDINO-BENZIMIDAZOLES, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS SANOFI-AVENTIS (DE) 2006-09-28 WO disclosed
WO-2006099941-A1 AMINOCARBONYL-SUBSTITUTED 8-N-BENZIMIDAZOLES, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS SANOFI-AVENTIS (DE) 2006-09-28 WO disclosed
WO-2006018117-A1 SUBSTITUTED 8-AMINOALKOXI-XANTHINES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2006-02-23 WO disclosed
WO-2006015701-A1 SUBSTITUTED, BICYCLIC 8-PYRROLIDINOXANTHINES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2006-02-16 WO disclosed
WO-2006015700-A1 SUBSTITUTED, BICYCLIC 8-PIPERIDINOXANTHINES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2006-02-16 WO disclosed
US-5610314-A Process for preparing dioxolenone derivatives used for making prodrug esters and intermediates BRISTOL-MYERS SQUIBB COMPANY (US) 1997-03-11 US disclosed
US-5567841-A ANTICHOLESTEROL AGENT BRISTOL-MYERS SQUIBB COMPANY (US) 1996-10-22 US disclosed
US-5470845-A Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia BRISTOL-MYERS SQUIBB COMPANY (US) 1995-11-28 US disclosed
EP-0595635-A1 Alpha-phosphorous substituted sulfonate derivatives as squalene synthetase inhibitors E.R. Squibb & Sons, Inc. (US) 1994-05-04 EP disclosed